A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors. Using an experimental therapy to target microscopic ...
Researchers found that treating precancerous pancreatic lesions with experimental KRAS inhibitors slowed tumor development ...
Depleting a clotting protein from the liver may help slow pancreatic cancer, according to a new study conducted by a team of researchers at the Indiana University Melvin and Bren Simon Comprehensive ...
HIGHLIGHTS Amplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US conferenceData showing narmafotinib activity in preclinical ...
A new report examines whether Iowa farmers, highly exposed to pesticides, are getting cancer more often than others in the ...
Stockhead on MSN
Health Check: Telix jumps first hurdle with its advanced prostate cancer therapy trial
In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ...
A month has gone by since the last earnings report for Exelixis (EXEL). Shares have lost about 2.8% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent ...
Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in difficult-to-treat cancersMechanisms ...
When Mark Pochapin, MD, director of the division of gastroenterology at New York City-based NYU Langone Health, came to the system in 2012, the GI division was relatively small and fragmented across ...
ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results